Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.60 |
| ▸ | YAP1 | P46937 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 8/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779718 | 1.00 | TEAD1 (0.60) | TEAD1YAP1BRD4SYKTNNI3K | |
| SCHEMBL22635634 | 1.00 | TEAD1 (0.60) | TEAD1YAP1BRD4SYKTNNI3K | |
| SCHEMBL20779716 | 1.00 | TEAD1 (0.60) | TEAD1YAP1BRD4SYKTNNI3K | |
| SCHEMBL20766526 | 0.87 | YAP1 (0.57) | TEAD1YAP1BRD4SYK | |
| SCHEMBL24496071 | 0.86 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL24496073 | 0.86 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL24496258 | 0.86 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL26669265 | 0.86 | TEAD1 (0.59) | TEAD1YAP1BRD4TNNI3K | |
| SCHEMBL24496015 | 0.84 | BRD4 (0.48) | TEAD1YAP1BRD4SYKITK | |
| SCHEMBL24496014 | 0.84 | BRD4 (0.48) | TEAD1YAP1BRD4SYKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561061-A | Combination of 3- (imidazol-4-yl) -4- (amino) -benzenesulfonamide TEAD inhibitors with EGFR inhibitors and/or MEK inhibitors for the treatment of lung cancer | 医肯纳肿瘤学公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4281073-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022159986-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |